BioGaia AB (publ) (LON:0GTN)

London flag London · Delayed Price · Currency is GBP · Price in SEK
108.80
+2.53 (2.38%)
At close: Jul 15, 2025
-14.73%
Market Cap835.13M
Revenue (ttm)109.43M
Net Income (ttm)23.88M
Shares Outn/a
EPS (ttm)0.24
PE Ratio34.97
Forward PE27.54
Dividend0.54 (0.50%)
Ex-Dividend DateMay 8, 2025
Volume30,625
Average Volume8,718
Open107.15
Previous Close106.27
Day's Range107.15 - 108.80
52-Week Range93.63 - 135.40
Beta0.62
RSI60.81
Earnings DateJul 18, 2025

About BioGaia AB

BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula. The Adult Health segment provides gut health tablets, bone health tablet... [Read more]

Industry Pharmaceutical Preparations
Founded 1990
Employees 225
Stock Exchange London Stock Exchange
Ticker Symbol 0GTN
Full Company Profile

Financial Performance

In 2024, BioGaia AB's revenue was 1.42 billion, an increase of 9.73% compared to the previous year's 1.30 billion. Earnings were 351.39 million, a decrease of -3.82%.

Financial numbers in SEK Financial Statements

News

There is no news available yet.